DexCom, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jacob Steven Leach
- Full Time Employees
- 11,050
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 6340 Sequence Drive San Diego CA United States of America 92121
- IPO Date
- Apr 14, 2005
- CIK
- 0001093557
- Website
- dexcom.com
- Similar Companies
- Business
- DexCom, Inc. is a leading medical technology firm dedicated to the engineering, production, and worldwide distribution of continuous glucose monitoring (CGM) solutions. The company's innovative systems are utilized by individuals managing diabetes, as well as by healthcare professionals, to facilitate enhanced glucose management. Its portfolio includes the sophisticated Dexcom G7 system, noted for its compact design, rapid warm-up, and all-in-one sensor with integrated transmitter, which stands as the most accurate CGM available and offers direct connectivity to smartwatches. Dexcom also provides the reliable Dexcom G6, an integrated CGM system, and the simplified Dexcom ONE, aimed at replacing routine fingerstick blood glucose testing for treatment decisions. Expanding its reach, Dexcom launched the Stelo Glucose Biosensor System in 2024, offering an over-the-counter CGM option for adults not on insulin, focusing on metabolic health and lifestyle insights. The company further empowers users with Dexcom Share, a remote monitoring feature, and the Dexcom Real-Time API, enabling third-party developers to integrate live CGM data into various digital health applications. Additionally, Dexcom Clarity provides a cloud-based platform for glucose trend analysis and reporting for both users and healthcare providers. In recent developments, Dexcom received FDA clearance in November 2025 for Dexcom Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin, slated for a December 2025 launch alongside an extended 15-day G7 sensor. Dexcom actively pursues partnerships, including collaborations with insulin pump manufacturers and digital health platforms to expand system compatibility. Founded in 1999, DexCom, Inc. is headquartered in San Diego, California, and maintains a global presence.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?
DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Average
Best Health & Fitness Stocks for Investors Amid Wellness Boom
DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?
DexCom: Still A Cautious Buy Following Earnings
DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Signal Robust Momentum
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
DexCom Q2 Earnings Call Highlights
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
Dexcom raises annual revenue forecast on strong demand for glucose monitors
Dexcom Reports Second Quarter 2026 Financial Results
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Dimensional Fund Advisors LP Buys 23,844 Shares of DexCom, Inc. $DXCM